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Background
Hemorrhagic cystitis (HC) is bleeding of the urinary bladder that results when the 
uroepithelium is damaged by toxins, drugs, radiation, viruses, or bacteria. The reported 
incidence in pediatric hemato-oncology patients undergoing hematopoietic stem cell 
transplantation (HSCT)/bone marrow transplantation (BMT) ranges from 10 to 70  % 
depending on the definition and grade (Gorczynska et al. 2005; Hassan et al. 2007; Vogeli 
et al. 1999; Vose et al. 1993). Persistent or severe HC is often associated with significant 
morbidity and may prolong the hospitalization of these patients (Hale et al. 2003).
Risk factors include bladder-toxic agents in the conditioning regimen for BMT or 
HSCT, and viruses or bacteria since the patient is immunosuppressed (Decker et  al. 
2009). Oxazaphosphorine compounds such as cyclophosphamide and ifosfamide are 
well-known causes of HC. Cyclophosphamide and ifosfamide are metabolized into acr-
olein, which causes uroepithelial damage and hemorrhage. Hematuria usually occurs 
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To find a relationship between clinical and sonographic appearance of hemorrhagic 
cystitis (HC) in pediatric hematooncology patients. Clinical and sonographic findings 
of 31 children (M:F = 18:13; mean age, 12.7 years) with HC in pediatric hematooncol-
ogy patients were reviewed. For each patient, the onset of HC after transplantation, use 
of bladder-toxic agent, presence of BK viruria, and duration of disease were reviewed. 
Sonographic findings including bladder wall thickness (BWT), the type of bladder wall 
thickening (nodular vs. diffuse), occurrence of hydronephrosis or pyelonephritis were 
reviewed. We analyzed sonographic appearance and clinical manifestations of HC. HC 
occurred within 4 months after HSCT/BMT. 27 patients (87.0 %) were positive for BK 
viruria and 24 patients (77.4 %) took bladder-toxic agents. On sonography, nodular type 
bladder wall thickening was more frequent (54.8 %), and BWT was thicker in this group 
(p = 0.003). There was a positive correlation between the BWT on initial sonography 
and duration of cystitis (r2 = 0.340). Hydronephrosis developed in 25.8 % of patients 
with HC, and as HC persisted longer, hydronephrosis occurred more (p = 0.004). In 
patients with HC after HSCT/BMT, the BWT on initial sonography correlates well with 
the duration of cystitis. And, longer time of HC develops the risk of hydronephrosis.
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within 48  h of using these drugs (Manikandan et  al. 2010; Stillwell and Benson 1988; 
Talar-Williams et al. 1996). Busulfan and alkylating agents like thiotepa, temozolomide, 
and 9-nitrocamptothecin (a topoisomerase I inhibitor) can also cause HC (Islam et al. 
2002).
Pediatric hemato-oncology patients are also susceptible to developing infectious HC 
because they are immunocompromised. BK polyomavirus, adenovirus types 7, 11, 34, 
and 35, cytomegalovirus (CMV), JC virus, and herpes virus have all been reported to 
cause HC (Erard et al. 2004). BK virus is ubiquitous and prevalent in the pediatric popu-
lation. After the initial infection, BK virus is thought to remain dormant and asympto-
matic in the kidneys and other organs. When patients become immunocompromised, 
BK virus can be reactivated, which may lead to HC (Leung et al. 2005).
In hemato-oncology patients who have been given cyclophosphamide, the sonographic 
findings of HC include diffuse or focal thickening of the urinary bladder (McCarville 
et al. 2000; Suzuki et al. 1988). Schechter et al. reported the sonographic presentation 
of HC associated with BK virus following HSCT; it was characterized as multiple small 
mural nodules in a background of diffuse bladder wall thickening (Schechter et al. 2010).
To the best of our knowledge, however, the relationship between the sonographic 
appearance and clinical parameters of HC has not been reported.
Therefore, this study examined the relationships between the sonographic findings 
and clinical manifestations of severe HC because it is often associated with significant 
morbidity and may result in prolonged hospitalization in pediatric hemato-oncology 
patients. We examined correlations between the sonographic findings and clinical 
parameters, such as disease duration or hydronephrosis, in patients with BK viruria or 
patients who received any bladder-toxic agent. We also analyzed the bladder wall thick-
ness (BWT) and type of bladder wall thickening and its association with prognosis, 
duration of disease, and complications of HC such as hydronephrosis or pyelonephritis.
Results
Thirty-one children were included in the study (M:F ratio  =  18:13; mean 
age =  12.7  years [range 5–17  years]) and HC occurred within 4  months after HSCT/
BMT (mean = 34.5 days [range 7–111 days]). Table 1 summarizes the clinical param-
eters and sonographic findings of the 31 patients. The mean duration of cystitis was 
46.6 days (range 4–236 days).
There was a significant positive correlation between the BWT on initial sonography 
and the duration of disease (r2 = 0.340).
Classifying patients by the type of bladder wall thickening, the nodular type was more 
frequent and was present in 17 patients (54.8 %) with HC. The nodular type BWT (mean 
17.8 mm) was significantly (p = 0.003) thicker than the diffuse type (mean = 10.0 mm). 
The mean disease duration, presence of hydronephrosis, and use of bladder-toxic agent 
or BK viruria did not differ significantly between the two groups (Table 2).
We also classified patients by the presence of BK viruria. Twenty-seven patients 
(87.0 %) were positive for BK virus on urine PCR. The pattern of bladder wall thickening, 
mean BWT, presence of hydronephrosis, and mean duration of disease in HC did not 
differ significantly between BK virus-positive and -negative groups (Table 3).
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We also subdivided the patients according to the use of a bladder-toxic agent. Twenty-
four patients (77.4 %) were given bladder-toxic agents such as cyclophosphamide, ifos-
famide, and busulfan as a conditioning regimen before transplantation, while seven 
Table 2 Analysis of  sonographic findings (mean BWT, hydronephrosis), clinical symptom 
(mean symptom duration of HC) and clinical conditions related to HC (use of bladder-toxic 
agent, BK viruria) between  two groups classified as  diffuse type HC group and  nodular 
type HC group
BWT bladder wall thickness
Diffuse type (n = 14) Nodular type (n = 17) p
Mean BWT (mm) 10.0 17.8 0.003
Mean duration of disease (days) 37.1 59.4 0.399
Hydronephrosis (n) 4 (28.6 %) 4 (23.5 %) 0.830
Bladder-toxic agent (n) 9 13 0.570
BK viruria (n) 12 (85.7 %) 15 (88.2 %) 0.622
Table 3 Analysis of sonographic findings (the type of bladder wall thickening, mean BWT) 
and  clinical symptom (mean symptom duration of  HC) between  two groups classified 
as positive BK viruria group and negative BK viruria group
BWT bladder wall thickness
BK viruria (+) (n = 27) BK viruria (−) (n = 4) p
Diffuse type (n) 12 (44.4 %) 2 (50.0 %) 0.622
Nodular type (n) 15 (55.6 %) 2 (50.0 %)
Mean BWT (mm) 14.7 11.7 0.263
Mean duration of disease (days) 49.5 48.2 0.536
Table 4 Analysis of sonographic findings (the type of bladder wall thickening, mean BWT), 
clinical symptom (mean symptom duration of HC) and clinical condition related to HC (BK 
viruria) between two groups classified as bladder-toxic agent taken group and not taken 
group
BWT bladder wall thickness
Bladder-toxic agent (+) (n = 24) Bladder-toxic agent (−) (n = 7) p
Diffuse type (n) 11 (45.8 %) 3 (42.9 %) 0.617
Nodular type (n) 13 (54.2 %) 4 (57.1 %)
BK viruria (n) 22 (91.7 %) 5 (71.2 %) 0.212
Mean BWT (mm) 15.1 11.5 0.202
Mean duration of disease (days) 54.5 31.9 0.267
Table 5 Analysis of sonographic findings (the type of bladder wall thickening, mean BWT) 
and  clinical symptom (mean symptom duration of  HC) between  two groups classified 
as hydronephrosis group and no hydronephrosis group
BWT bladder wall thickness
Hydronephrosis (+) (n = 8) Hydronephrosis (−) (n = 23) p
Diffuse type (n) 4 10 0.534
Nodular type (n) 4 13
Mean BWT (mm) 16.6 13.5 0.362
Mean duration of disease (days) 86.3 36.5 0.004
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patients did not take bladder-toxic agents. The pattern of bladder wall thickening, mean 
BWT, BK viruria, presence of hydronephrosis, and mean duration of disease in HC did 
not differ significantly between the two groups (Table 4).
Hydronephrosis developed in eight patients with HC (Table 5; Fig. 1). Equal numbers 
of patients with hydronephrosis had diffuse and nodular type wall thickening. The mean 
BWT on initial sonography was 16.6 mm in patients with hydronephrosis and 13.5 mm 
in those without hydronephrosis. The occurrence of hydronephrosis was not correlated 
with BWT (p = 0.362). The mean duration of disease was significantly (p = 0.004) longer 
in patients with hydronephrosis (86.3  days) than in patients without hydronephrosis 
(36.5 days).
One of the eight patients (12.5 %) who developed hydronephrosis underwent a per-
cutaneous nephrostomy for severe obstructive nephropathy. Two of the eight patients 
(25.0 %) who developed hydronephrosis developed pyelonephritis.
Discussion
Hemorrhagic cystitis can be classified as early or late onset by the onset time after trans-
plantation. Early onset HC occurs within the first 2–3 days after transplantation and is 
thought to be a complication of thrombocytopenia and bladder-toxic agents in the con-
ditioning regimen, such as cyclophosphamide, ifosfamide, or busulfan. Late-onset HC 
usually occurs several weeks after transplantation and is thought to be immune-related. 
An immunocompromised state (depressed cellular immunity, donor T-cell depletion, or 
graft-versus-host disease) may lead to viral infections, such as BK virus, JC virus, CMV 
and adenovirus 11, which may result in HC (Decker et al. 2009).
The mechanism of drug-induced early onset HC has been reported. Oxazaphospho-
rine compounds such as cyclophosphamide and ifosfamide are commonly used for mye-
loablative conditioning before transplantation. Cyclophosphamide is broken down into 
hydroxycyclophosphamide in hepatic microsomal cells, and then hydroxycyclophospha-
mide is converted into aldophosphamide by target cells. The aldophosphamide is con-
verted into phosphoramide mustard, which is the active antineoplastic metabolite, and 
Fig. 1 An 8-year-old girl with hemorrhagic cystitis (15th day after hematopoietic stem cell transplantation for 
aplastic anemia). a Sonography of the bladder shows diffuse type wall thickening of bladder. b Hydronephro-
sis developed at 23th day after the onset of hemorrhagic cystitis
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acrolein, which has no significant antineoplastic activity, but is toxic to the urothelium 
(Schoenike and Dana 1990). Similarly, ifosfamide, which is a synthetic analogue of cyclo-
phosphamide, is metabolized to iphosphoramide mustard and acrolein (Manikandan 
et al. 2010). The urinary bladder can be damaged with prolonged exposure of the urothe-
lium to acrolein (Ribeiro et al. 2002). Acrolein triggers the release of several inflamma-
tory mediators, such as tumor necrosis factor-alpha, interleukin-1 beta, and endogenous 
nitric oxide (Ribeiro et  al. 2002). These inflammatory mediators can result in bladder 
mucosal edema, vascular dilatation, and increased capillary fragility, which may cause 
urothelial hemorrhage. In chronic cases, progressive fibrosis of the wall can result in a 
small fibrotic non-compliant bladder (Kimura et  al. 1998). Mesna (2-mercaptoethan-
sulfonate-natrium; Uromitexan®) is an organosulfur compound that is used as an adju-
vant in cancer chemotherapy with cyclophosphamide and ifosfamide. Mesna assists in 
detoxifying acrolein when the sulfhydryl group of the former reacts with the vinyl group 
of the latter. Hematuria usually occurs within 48  h of using these drugs (Stillwell and 
Benson 1988). Busulfan, an alkyl sulfonate compound used to treat chronic granulocytic 
leukemia, causes HC in about 24 % of patients (Ringden et al. 1994). However, the role 
of busulfan and its metabolites is not completely known. Other alkylating agents like thi-
otepa, temozolomide, and 9-nitrocamptothecin (a topoisomerase I inhibitor) have also 
been reported to cause HC (Islam et al. 2002).
The BK polyomavirus, adenovirus types 7, 11, 34, and 35, cytomegalovirus, JC virus, 
and herpes virus have been reported to cause HC (Erard et al. 2004).
Human BK polyomavirus can cause HC after HSCT. Human BK polyomavirus (or pol-
yomavirus hominis 1) is ubiquitous and more than 80 % of the adult population has been 
exposed to it. After a primary infection that is usually asymptomatic, the virus remains 
dormant in the urinary tract (including the kidneys and uroepithelium of the bladder), 
lymphoid tissues, and circulating leucocytes. In patients with impaired immunity (such 
as pregnancy, diabetes, or the elderly) or with depressed cellular immunity, reactivation 
can occur with increased virus replication and viruria (Leung et al. 2005).
Leung et al. proposed a model of HC in allogenic HSCT. Bladder-toxic agents usually 
damage the uroepithelium, which may result in an environment favoring the replication 
of BK virus. Then, the patient’s immunosuppression allows viral reactivation and replica-
tion. Alloimmune attack by donor lymphoid cells against BK viral antigens perpetuates 
the mucosal damage (Leung et al. 2005).
Schechter et al. reported that the sonographic findings of HC associated with BK virus 
following HSCT is characterized by multiple small mural nodules in a background of 
diffuse bladder wall thickening (Schechter et al. 2010).
To the best of our knowledge, there are only a few reports on the normal wall thick-
ness of the urinary bladder. Kuzmic et al. reported that the respective normal detrusor 
thicknesses of the anterior, posterior, right lateral, and left lateral walls were 1.2 ± 0.4, 
1.2 ± 0.4, 1.2 ± 0.4, and 1.2 ± 0.4 mm in healthy children younger than 18 years old, 
and they did not find a significant difference in the thicknesses of the four walls (Kuzmic 
et al. 2001). Based on their result, we measured the thickest point of the urinary bladder. 
If the site of measurement is fixed, then the BWT in nodular type HC might be meas-
ured in an area where it is thinner than average.
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Many studies have suggested that multiple factors affect the development of HC. Con-
sequently, we classified our patients according to the clinical settings and sonographic 
findings.
Classifying our patients by the type of bladder wall thickening, the mean disease dura-
tion and occurrence of hydronephrosis did not differ significantly between these two 
groups, in contrast to the use of bladder-toxic agents and BK viruria. The presence of BK 
viruria or the use of a bladder-toxic agent was not correlated with BWT, type of bladder 
wall thickening, or disease duration in our study. The occurrence of hydronephrosis was 
not correlated with BWT.
Nevertheless, we obtained several significant results. BWT on the initial sonography 
was positively correlated with the disease duration; the duration of disease increased 
with the BWT on initial sonography. Hydronephrosis occurred in 25.8 % of the patients 
with HC, and the incidence of hydronephrosis increased with the duration of HC. About 
13.5 % of the patients who developed hydronephrosis underwent percutaneous nephros-
tomy for obstructive nephropathy and 25.0 % of the patients who developed hydrone-
phrosis developed pyelonephritis. Eleven patients took cidofovir and 10 (90.9 %) of them 
did not develop hydronephrosis. We suggest that the use of cidofovir may help to pre-
vent hydronephrosis and shorten the duration of HC in patients. The mean duration of 
HC without the occurrence of hydronephrosis was 36.5 days. A prospective randomized 
study of this is warranted.
In this study, all of the patients given cyclophosphamide as conditioning chemother-
apy were also given Mesna. Eighteen patients used Mesna as prophylaxis for HC. Mesna 
binds acrolein, the urotoxic metabolite of cyclophosphamide and ifosfamide, in the uri-
nary system and blocks acrolein from entering uroepithelial cells. Experimental and 
clinical studies have clearly demonstrated that Mesna is effective against cyclophospha-
mide-induced HC (Haselberger and Schwinghammer 1995). Nevertheless, about 5 % of 
the patients treated with cyclophosphamide or ifosfamide develop HC (Etlik et al. 1997; 
Shepherd et al. 1991). None of the patients given the bladder-toxic agent busulfan were 
given Mesna. No prophylactic drug for busulfan is known because the roles of busulfan 
and its metabolites are not clear. Hence, any patient given a bladder-toxic agent needs to 
be watched carefully, and if these patients complain of urinary symptoms, further evalu-
ation, such as sonography, should be performed.
There were several limitations to our study. We calculated the volume of the bladder 
if it appeared to have collapsed. When the volume of the bladder was less than 50 % of 
its normal estimated capacity, the sonography examination was delayed for a few hours. 
Since this study was retrospective, the bladder volume was not measured in every case. 
An accurate estimation of volume was not always possible, although we rechecked the 
calculation, because our patients were children with frequency and dysuria. Therefore, 
this study had a limitation in terms of the standardization of bladder filling status.
Conclusion
In conclusion, in patients with HC after HSCT/BMT, the BWT on the initial sonography 
may correlate with the symptom duration, and the duration of disease correlates with 
the occurrence of hydronephrosis.
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Methods
Patients
Our Institutional Review Board approved this retrospective study and waived the 
requirement for informed consent. The clinical course and sonography of HC patients 
who underwent HSCT/BMT at our hospital between May 2009 and July 2014 were 
reviewed. All children were younger than 17  years of age and the medical charts and 
sonographic images of 31 patients were reviewed retrospectively.
The following data were collected for analysis: patient age, sex, and underlying disease, 
the day of HSCT/BMT, use of a bladder-toxic agent in a conditioning regimen, dates of 
HC diagnosis and normalized urinalysis, symptom duration (number of days), and urine 
PCR results for BK virus. Quantitative PCR for BK virus was performed on urine sam-
ples collected before HSCT/BMT and when HC developed after transplantation.
We also reviewed the initial and serial sonographic findings, including BWT, the type 
of BWT, and presence of hydronephrosis or pyelonephritis. Follow-up sonographic 
exams were performed at 1-week intervals until complete resolution of any microscopic 
hematuria and urinary symptoms.
We correlated the sonographic appearance with the clinical manifestations of HC for 
each patient.
Definitions
HC, onset of HC, duration of disease
Droller et al. proposed a grading system for HC in which grade I HC is defined as the 
presence of microscopic hematuria and urinary symptoms such as frequency, urgency, 
or dysuria (Droller et  al. 1982). Therefore, we selected patients with HC if the patient 
had at least microscopic hematuria (grade I HC) and urinary symptoms. Eleven patients 
had gross hematuria. We defined the onset of HC as the number of days from the date 
when the patient underwent HSCT/BMT to the date on which HC was diagnosed. We 
defined the duration of disease as the number of days from the date of diagnosis of HC 
to the date on which the patient’s urinalysis normalized. In other words, symptom dura-
tion was defined as the number of days with microscopic hematuria on urinalysis.
Microscopic hematuria was defined as >3 red blood cells (RBCs) per high-power field 
on two of three specimens, and normalized microscopic hematuria was defined as <3 
RBCs per high-power field on urinalysis.
BWT and type of BWT on sonography
Abnormal bladder wall thickening was defined as wall thickness >3 mm. The BWT was 
measured by the radiologists who performed the sonographic examination. In our clinic, 
the BWT is routinely reported if patients have urinary symptoms or an abnormal uri-
nalysis. If these patients have follow-up sonographic examinations, the changes in BMT 
are usually reported.
In our clinic, kidney and bladder sonography are performed with bladder filling at least 
3 h before the examination. If a patient does not meet this condition, the examination is 
delayed for a few hours. Even if the patient meets this condition, the examination might 
be repeated if the radiologist decides that the bladder is not fully distended. If the radi-
ologist thought that the bladder had collapsed, the volume of the bladder was measured 
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and the examination delayed. The urinary bladder was considered not fully distended 
when the bladder volume was less than 50 % of the normal volume for age. The volume 
of the bladder (V) in milliliters was calculated using the formula (Norgaard et al. 1998):
where a is the bladder width, b is the anteroposterior diameter, and c is the craniocau-
dal diameter, all measured by sonography. The calculated volume of the bladder was 
compared with the normal estimated bladder capacity (EBC) for age, using the formula 
(Norgaard et al. 1998):
If the bladder volume was less than 50  % of the EBC, the measurement of BWT was 
delayed for a few hours.
On sonography, the BWT was measured as the hypoechoic layer sandwiched between 
two hyperechoic layers (the uroepithelium and perivesical tissue) at the thickest of four 
points in the urinary bladder, i.e., the anterior, posterior, right lateral, and left lateral 
walls.
The BWT was classified into ‘diffuse’ and ‘nodular’ types. Diffuse bladder wall thicken-
ing comprised continuous, even wall thickening of bladder. In the nodular type, there 
were nodular protrusions >3 mm high in a background of either continuous or discon-
tinuous bladder wall thickening (Fig. 2).
Statistical analysis
Statistical analysis was performed using the SPSS for Windows software package (ver. 
19.0; IBM Corp., Armonk, NY, USA).
A p value <0.05 indicated statistical significance. The Pearson correlation coefficient 
was calculated to determine the relationship between the BWT on initial sonography 
V = a × b × c × 0.55
EBC =
(
age in years × 30
)
+ 30
Fig. 2 Two types of bladder wall thickening on bladder sonography of patients with hemorrhagic cystitis. a 
Diffuse type wall thickening; continuous, circumferential and even wall thickening of bladder. b Nodular type 
wall thickening; more than 3 mm-height of nodular protruding focus in a background of either continuous or 
discontinuous wall thickening of bladder
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and the duration of disease. The Mann–Whitney U-test was used to compare the other 
variables.
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